CLAIMS

1. An antibody-drug conjugate comprising:

a. an antigen binding protein (Ab) which binds ~~to the extracellular domain of~~ human Tissue Factor (TF) (SEQ ID NO:810), wherein the Ab comprises three heavy chain complementarity determining regions (CDRs) (a VH-CDR1, a VH-CDR2, and a VH-CDR3~~,~~) and three light chain CDRs (a VL-CDR1, a VL-CDR2, and a VL-CDR3~~,~~), wherein

i. the VH-CDR1 comprises the sequence of SEQ ID NO: 872, the VH-CDR2 comprises the sequence of SEQ ID NO: 873, the VH-CDR3 comprises the sequence of SEQ ID NO: 874, the VL-CDR1 comprises the sequence of SEQ ID NO: 875, the VL-CDR2 comprises the sequence of SEQ ID NO: 876, and the VL-CDR3 comprises the sequence of SEQ ID NO: 877,

ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody~~Ab designated 25A3,

iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody~~Ab designated 25A,


iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody~~Ab designated 25A5,

v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody~~Ab designated 25A5-T, or

vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody~~Ab designated 25G1;

and

b. one or more linker-toxin moieties represented by Formula IV:



Formula IV


wherein:

X is *-C(O)NHCH($CH_2(R^2)$)-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula IV, or X is absent;

L is a linker;

! represents the point of attachment of L to the Ab, where L is attached to the Ab through a covalent bond;


R^1 is selected from the group consisting of:



wherein # and % represent the respective points of attachment as indicated in Formula IV; and


R^2 is phenyl.

2. The antibody-drug conjugate of claim 0, wherein ~~R^1 is selected from the group consisting of:~~




~~**3.** The antibody-drug conjugate of claim 1 or claim 2, wherein X is absent.~~

~~**4.** The antibody-drug conjugate of any one of claims 1-3, wherein the linker-toxin moiety of Formula IV is represented by Formula V:~~




~~**Formula V**~~


~~**5.** The antibody-drug conjugate of claim 4, wherein R^1 is selected from the group consisting of:~~



~~**6.** The antibody-drug conjugate of claim 4 or claim 5, wherein R^1 is selected from the group consisting of:~~



~~**7.** and .claims 4-6, wherein R^1 is:~~




~~**8.** The antibody-drug conjugate of any one of the preceding claims, wherein~~ L is a cleavable linker~~.~~

~~**9.** The antibody-drug conjugate of any one of the preceding claims, wherein,~~ and/or L is a peptide-containing linker~~.~~; or

~~**10.** The antibody-drug conjugate of any one the preceding claims, wherein L is a protease-cleavable linker.~~

~~11.~~ ~~The antibody-drug conjugate of any one of claims 1-7, wherein~~ L is a linker selected from one of N-(β-maleimidopropyloxy)-N-hydroxy succinimide ester (BMPS), N-(ε-maleimidocaproyloxy) succinimide ester (EMCS), N-[γ-maleimidobutyryloxy]succinimide ester (GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate (SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl 6-[(β-maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, sulfo-SMPB, and succinimidyl-(4-vinylsulfone)benzoate (SVSB~~).~~); and/or


~~12.~~ ~~The antibody-drug conjugate of any one of claims 1-7, wherein~~(ii) L comprises a poly(ethylene)glycol chain of the formula:



wherein g is an integer from 1-20.

~~**13.** The antibody-drug conjugate of claim 12, wherein g is 3.~~

~~**14.** An antibody-drug conjugate of Formula VI:~~



Formula VI

wherein:


Ab represents a tissue factor (TF) antibody;

n is an integer greater than or equal to 1;


X is *-C(O)NHCH(CH_2(R^2))-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula VI, or X is absent;

L is a linker;


R^1 is selected from the group consisting of:




,




,



,



, and



,

wherein # and % represent the respective points of attachment as indicated in Formula VI; and

R^2 is phenyl; and wherein

the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein

i. the VH-CDR1 comprises SEQ ID NO: 872, the VH-CDR2 comprises SEQ ID NO: 873, the VH-CDR3 comprises SEQ ID NO: 874, the VL-CDR1 comprises SEQ ID NO: 875, the VL-CDR2 comprises SEQ ID NO: 876, and the VL-CDR3 comprises SEQ ID NO: 877,

ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A3,


iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A,

iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5,

v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5-T, or

vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25G1.


15. The antibody-drug conjugate of claim 14, wherein R^1 is selected from the group consisting of:



, , and .


16. The antibody-drug conjugate of claim 14 or 15, wherein X is absent.

17. The antibody-drug conjugate of claim 15 or claim 16, wherein R^1 is selected from the group consisting of:



and .

18. The antibody-drug conjugate of any one of claims 15-17, wherein R^1 is:



.

19. The antibody-drug conjugate of any one of claims 16-17, wherein L is a cleavable linker.


20. The antibody-drug conjugate of any one of claims 14-19, wherein L is a peptide-containing linker.

21. The antibody-drug conjugate of any one of claims 14-19, wherein L is a protease-cleavable linker.

22. The antibody-drug conjugate of any one of claims 14-19, wherein L is a linker selected from one of N-(β-maleimidopropyloxy)-N-hydroxy succinimide ester (BMPS), N-(ε-maleimidocaproyloxy) succinimide ester (EMCS), N-[γ-maleimidobutyryloxy]succinimide ester (GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC), m-

~~maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate (SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl 4-(2-pyridylthio)pentanoate (SPP), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl 6-[(β-maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, sulfo-SMPB, and succinimidyl-(4-vinylsulfone)benzoate (SVSB).~~


~~**23.** The antibody-drug conjugate of any one of claims 14-19, wherein L comprises a poly(ethylene)glycol chain of the formula:~~



~~wherein g is an integer from 1-20.~~

~~**24.** The antibody-drug conjugate of claim 23, wherein g is 3.~~

~~**25.**__**3.**__ The antibody-drug conjugate of claim ~~14,~~1, wherein L is represented by Formula VII:



Formula VII

wherein:

Z represents a functional group that binds to a target group of the ~~TF-antibody~~Ab;

D represents the point of attachment to the amino group as indicated in Formula ~~VI~~IV;

Str is a stretcher;

AA_1 and AA_2 are each independently an amino acid, wherein AA_1-$[AA_2]_m$ forms a protease cleavage site;

X_1 is a self-immolative group;

s is an integer selected from ~~0~~1 and ~~1~~0;

m is an integer selected from the group consisting of 1, 2, 3, and 4;

o is an integer selected from 0, 1, and 2~~.~~,

~~**26.** The antibody-drug conjugate of claim 25,~~optionally wherein ~~n is an integer selected from~~ the ~~group consisting of~~one or more linker-toxin moieties represented by Formula IV are 1, 2, 3, 4~~, and~~ or 5~~.~~ linker-toxin moieties represented by Formula IV,

~~The antibody-drug conjugate of claim 25 or claim 26, wherein~~ optionally wherein:


~~**27.**~~ $[Str]_s$ is selected from the group consisting of alkylene, stretchers based on aliphatic acids, stretchers based on aliphatic diacids, stretchers based on aliphatic amines and stretchers based on aliphatic diamines~~.~~; and/or

~~**28.** The antibody-drug conjugate of any one of claims 25-27, wherein~~ $[Str]_s$ is selected from the group consisting of diglycolate-based stretchers, malonate-based stretchers, caproate-based stretchers and caproamide-based stretchers~~.~~;

~~The antibody-drug conjugate of claim 25 or claim 26, wherein~~ and/or


~~**29.**~~ $[Str]_s$ is selected from the group consisting of glycine-based stretchers, polyethylene glycol-based stretchers, and monomethoxy polyethylene glycol-based stretchers~~.~~;

~~**30.** The antibody-drug conjugate of claim 25 or claim 26, wherein $[Str]_s$ is:~~



and/or

$[Str]_s$ is:



wherein

h is an integer from 1-20,


CC refers to the point of attachment to AA_1; and


DD refers to the point of attachment to Z~~.~~;


~~The antibody-drug conjugate of claim 25~~


or ~~claim 26, wherein~~


~~31.~~ $[Str]_s$ is selected from the group consisting of:





~~,~~



~~,~~



~~,~~



~~,~~






,


,


,


,


, and




;

wherein:

EE and FF represent the points of attachment to Z and AA_1, respectively;

R is selected from hydrogen and C_1-C_6 alkyl;


each occurrence of p is independently an integer from 2 to 10; and


each occurrence of q is independently an integer from 1 to 10~~.~~;


~~32. The antibody-drug conjugate of claim 25, claim 26,~~


and/or ~~claim 31, wherein~~

$[Str]_s$ is selected from the group consisting of:



,


, and




,


wherein:

EE and FF represent the points of attachment to Z and AA_1, respectively;


each occurrence of p is independently an integer from 2 to 10; and

each occurrence of q is independently an integer from 1 to 10~~.~~;

~~**32.** The antibody-drug conjugate of claim 25, claim 26, claim 31, or claim 32, wherein $[Str]_s$ is selected from:~~





~~and~~



and/or

$[Str]_s$ is selected from the group consisting of:



and


,

wherein:

EE and FF represent the points of attachment to Z and AA_1, respectively;

each occurrence of p is independently an integer from 2 to 6, and

q is an integer from 2 to 8.

4. ~~**34.**~~ The antibody-drug conjugate of ~~any one of claims 25-33,~~claim 3, wherein~~:~~

AA_1-$[AA_2]_m$ is selected from Val-Lys, Ala-Lys, Phe-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Trp-Cit, Phe-Arg, Ala-Phe, Val-Ala, Met-Lys, Asn-Lys, Ile-Pro, Ile-Val, Asp-Val, His-Val,

Met-(D)Lys, Asn-(D)Lys, Val-(D)Asp, NorVal-(D)Asp, Ala-(D)Asp, Me_3Lys-Pro, PhenylGly-(D)Lys, Met-(D)Lys, Asn-(D)Lys, Pro-(D)Lys, Met-(D)Lys, Met-Cit-Val, Gly-Cit-Val, (D)Phe-Phe-Lys, (D)Ala-Phe-Lys, Gly-Phe-Leu-Gly~~,~~ (SEQ ID NO: 922), and Ala-Leu-Ala-Leu~~.~~ (SEQ ID NO: 923); and/or

~~**35.** The antibody-drug conjugate of any one of claims 25-34, wherein~~ m is selected from 1, 2, and 3~~.~~; and/or

~~**36.** The antibody-drug conjugate of any one of claims 25-35, wherein m is 1.~~

~~**37.** The antibody-drug conjugate of any one of claims 25-36, wherein~~ AA_1-$[AA_2]_m$ is a dipeptide selected from Val-Lys, Ala-Lys, Phe-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit and Trp-Cit~~.~~; and/or

~~**38.** The antibody-drug conjugate of any one of claims 25-37, wherein~~ each X_1 is independently selected from p-aminobenzyloxycarbonyl (PABC), p-aminobenzyl ether (PABE) and methylated ethylene diamine (MED~~).~~); and/or

s is 1, and optionally h is 3; and/or


o is 0

~~**39.**~~**5.** The antibody~~-~~ drug~~-~~conjugate of claim ~~30~~1, wherein~~ s is 1 and h is 3.~~;

~~**40.** The antibody-drug conjugate of any one of claims 25-39, wherein s is 1.~~

~~**41.** The antibody-drug conjugate of any one of claims 25-40, wherein~~ the ~~o is 0.~~


~~**42.** An antibody-drug conjugate comprising a~~ linker-toxin moiety is of the Formula VIII:



Formula VIII

wherein ## represents the point of attachment of the linker-toxin moiety to the ~~TF antibody and the linker-toxin moiety is attached to the TF antibody~~ Ab through a covalent bond~~.~~

~~**43.** An antibody-drug conjugate of Formula IX:~~



Ab is a tissue factor (TF) antibody, wherein the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein

i. the VH-CDR1 comprises SEQ ID NO: 872, the VH-CDR2 comprises SEQ ID NO: 873, the VH-CDR3 comprises SEQ ID NO: 874, the VL-CDR1 comprises SEQ ID NO: 875, the VL-CDR2 comprises SEQ ID NO: 876, and the VL-CDR3 comprises SEQ ID NO: 877,

ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A3,

iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A,

iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5,

v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5-T,; or

vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25G1,

n is an integer greater than or equal to 1, and

the succinimidyl group is attached to the Ab through a covalent bond.


44. The antibody-drug conjugate of claim 43, wherein n is selected from the group consisting of 1, 2, 3, 4, and 5.

45. The antibody-drug conjugate of claim 43 or 44, wherein n is selected from the group consisting of 2, 3, and 4.

~~**46.** An antibody-drug conjugate comprising a linker~~

the linker L is:

as represented by Formula X:



Formula X

wherein:

is the point of attachment to the ~~antibody~~Ab and the succinimidyl group is attached to the ~~antibody~~Ab through a covalent bond;~~-~~

~~Y is one or more additional linker components, or is absent; and~~

~~D_1 is the point of attachment to a cytotoxic agent, and wherein~~

~~the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein~~

~~i. the VH-CDR1 comprises SEQ ID NO: 872, the VH-CDR2 comprises SEQ ID NO: 873, the VH-CDR3 comprises SEQ ID NO: 874, the VL-CDR1 comprises SEQ ID NO: 875, the VL-CDR2 comprises SEQ ID NO: 876, and the VL-CDR3 comprises SEQ ID NO: 877,~~

~~ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A3,~~


~~iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A,~~

~~iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5,~~

~~v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5-T, or~~

vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25G1.

47. An antibody-drug conjugate comprising a linker as represented by Formula XI:



Formula XI

wherein:


is the point of attachment to the antibody and the succinimidyl group is attached to the antibody through a covalent bond;

Y is one or more additional linker components, or is absent; and

D_1 is the point of attachment to a cytotoxic agent, and wherein the toxin;

or

as represented by Formula XI:



Formula XI

wherein:

is the point of attachment to the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein

i. the VH-CDR1 comprises SEQ ID NO: 872, the VH-CDR2 comprises SEQ ID NO: 873, succinimidyl group is attached to the VH-CDR3 comprises SEQ ID NO: 874,

~~the VL-CDR1 comprises SEQ ID NO: 875, the VL-CDR2 comprises SEQ ID NO: 876, and the VL-CDR3 comprises SEQ ID NO: 877,~~Ab through a covalent bond;

~~ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A3,~~

~~iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A,~~

~~iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5,~~

~~v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5-T, or~~

~~vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25G1.~~

~~**48.** The antibody-drug conjugate of claim 46 or claim 47, wherein the cytotoxic agent is selected from the group consisting of a diagnostic agent, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound, or a chemiluminescent compound.~~

~~**49.** The antibody-drug conjugate of claim 46 or claim 47, wherein the cytotoxic agent is a cytotoxic payload having an improved safety profile.~~

Y is one or more additional linker components, or is absent; and

D_1 is the point of attachment to the toxin.

~~**50.**~~**6.** The antibody-drug conjugate of any one of ~~the preceding~~ claims 1-5, wherein the Ab comprises:

a. a variable heavy (VH) sequence ~~that is~~shown in SEQ ID NO: 868 and a variable light (VL) sequence ~~that is~~shown in SEQ ID NO: 869,

b. a VH ~~that is~~sequence shown in SEQ ID NO: 151 and a VL sequence ~~that is~~shown in SEQ ID NO: 152,

c. a VH sequence ~~that is~~shown in SEQ ID NO: 113 and a VL sequence ~~that is~~shown in SEQ ID NO: 114,

d. a VH sequence ~~that is~~shown in SEQ ID NO: 189 and a VL sequence ~~that is~~shown in SEQ ID NO: 190,

e. a VH sequence ~~that is~~shown in SEQ ID NO: 836 and a VL sequence ~~that is~~shown in SEQ ID NO: 837, or

f. a VH sequence ~~that is~~shown in SEQ ID NO: 265 and a VL sequence ~~that is~~shown in SEQ ID NO: 266.

~~51.~~7. The antibody-drug conjugate of any one of ~~the preceding~~ claims 1-6, wherein the Ab comprises:

a. a heavy chain sequence ~~that is~~comprising
QVQLVQSGAEVKKPGASVKVSCKASGYTFDx[V/A]YGISWVRQAPGQ
GLEWMGWIAPYx[N/S]GNTNYAQKLQGRVTMTTDTSTSTAYMELRSL
RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 924)
and a light chain sequence ~~that is~~comprising
DIQMTQSPSTLSASVGDRVTITCx[R/Q]ASx[Q/E]SIx[S/N]x[S/N]WLAW
YQQKPGKAPKLLIYKAx[S/Y]x[S/N]LEx[S/Y]GVPSRFSGSGSGTEFTLTI
SSLQPDDFATYYCQx[Q/L]FQx[S/K]LPPFTFGGGTKVEIKRTVAAPSVFI
FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT
EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG
EC~~,~~ (SEQ ID NO: 942),

b. a heavy chain sequence ~~that is~~comprising
QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLE
WMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTA
VYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSK
STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY

VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS
NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 926) and a light chain sequence ~~that is~~comprising
DIQMTQSPSTLSASVGDRVTITCQASQSINNWLAWYQQKPGKAPKLLI
YKAYNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFT
FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
CEVTHQGLSSPVTKSFNRGEC~~,~~ (SEQ ID NO: 927),

c. ~~a heavy chain sequence that is~~
~~QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLE
WMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTA
VYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSK
STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS
NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG and a light chain sequence that is~~a heavy chain sequence comprising
QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQA
PGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL
RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 926)
and a light chain sequence comprising

DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIY
KASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQFQSLPPFTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC~~,~~ (SEQ ID NO: 928),


d. ~~a heavy chain sequence that is~~ ~~QVQLVQSGAEVKKPGASVKVSCKASGYTFDAYGISWVRQAPGQGLE~~
~~WMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTA~~
~~VYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSK~~
~~STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS~~
~~LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP~~
~~APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY~~
~~VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS~~
~~NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY~~
~~PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG~~
~~NVFSCSVMHEALHNHYTQKSLSLSPG and a light chain sequence that is~~a heavy chain sequence comprising~~QVQLVQSGAEVKKPGASVKVSCKASGYTFDAYGISWVRQA~~
~~PGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL~~
~~RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF~~
~~PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL~~
~~QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK~~
~~THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP~~
~~EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG~~
~~KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS~~
~~LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV~~
~~DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 929)~~
and a light chain sequence comprising
DIQMTQSPSTLSASVGDRVTITCRASESISNWLAWYQQKPGKAPKLLIY
KAYSLEYGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQFQKLPPFTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC~~,~~ (SEQ ID NO: 930),

e. ~~a heavy chain sequence that is~~ ~~QVQLVQSGAEVKKPGASVKVSCKASGYTFRSYGISWVRQAPGQGLE WMGWVAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDT AVYYCARDAGTYSPYGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPG and a light chain sequence that is~~ ~~is~~a heavy chain sequence comprising QVQLVQSGAEVKKPGASVKVSCKASGYTFRSYGISWVRQA PGQGLEWMGWVAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL RSDDTAVYYCARDAGTYSPYGYGMDVWGQGTTVTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 931) and a light chain sequence comprising DIQMTQSPSTLSASVGDRVTITCRASHSIDSWLAWYQQKPGKAPKLLI YKASYLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFT FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC~~,~~ (SEQ ID NO: 932), or

f. ~~a heavy chain sequence that is~~ ~~QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLE WMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTA VYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS~~

~~LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPG and a light chain sequence that is~~a heavy chain sequence comprising QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQA PGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 926) and a light chain sequence comprising DIQMTQSPSTLSASVGDRVTITCRASESISNWLAWYQQKPGKAPKLLIY KAYSLEYGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQFQKLPPFTF GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC~~.~~ (SEQ ID NO: 930).


~~52.~~ 8. The ~~An~~ antibody-drug conjugate of ~~Formula IX:~~



~~Formula IX~~

~~wherein:~~

~~Ab is a tissue factor (TF) antibody~~claim 1, wherein the antibody-drug conjugate has Formula IX:



Formula IX

wherein:

the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the ~~antibody~~Ab designated 25A3, and

n is an integer greater than or equal to 1~~.~~

~~**53.** The antibody-drug conjugate of claim 52,~~, optionally wherein n is selected from the group consisting of 1, 2, 3, 4, and 5~~.~~;

~~**54.** The antibody-drug conjugate of claim 52, wherein n is selected from the group consisting of 2, 3, and 4.~~

~~The antibody-drug conjugate of any one of claims 52-54, wherein~~ optionally wherein


~~**55.**~~ the Ab comprises a variable heavy (VH) sequence ~~that is~~shown in SEQ ID NO: 151 and a variable light (VL) sequence ~~that is~~shown in SEQ ID NO: 152~~.~~; and/or

~~**56.** The antibody-drug conjugate of any one of claims 52-55, wherein~~ the Ab comprises a ~~full~~ heavy chain sequence ~~that is~~comprising

QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLEWMGWIAPYS
GNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDAGTYSPFGYGM
DVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG
ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS
CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP
G (SEQ ID NO: 926) and a light chain sequence ~~that is~~comprising
DIQMTQSPSTLSASVGDRVTITCQASQSINNWLAWYQQKPGKAPKLLIYKAYNLESG
VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFTFGGGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY
SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 927).

~~**57.** An antibody-drug conjugate of Formula IX:~~



~~**Formula IX**~~

~~wherein:~~

~~Ab is a tissue factor (TF) antibody, wherein the Ab comprises a heavy chain sequence that is~~
~~QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLEWMGW~~
~~IAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDAG~~
~~TYSPFGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK~~
~~DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN~~
~~VNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS~~
~~RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV~~
~~LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE~~
~~MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK~~
~~LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG and a light chain sequence that is~~
~~DIQMTQSPSTLSASVGDRVTITCQASQSINNWLAWYQQKPGKAPKLLIYKAY~~


NLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFTFGGGTKVEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC, and

n is an integer greater than or equal to 1.

58. The antibody-drug conjugate of claim 57, wherein n is selected from the group consisting of 1, 2, 3, 4, and 5.

59. The antibody-drug conjugate of claim 57, wherein n is selected from the group consisting of 2, 3, and 4.

60. An antibody-drug conjugate comprising an antibody (Ab) and one or more linker-toxins of the following structure:



;

wherein:


Ab is a tissue factor (TF) antibody, wherein the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the antibody designated 25A3;

the one or more linker-toxins are attached to the Ab through a covalent bond; and

represents a point of attachment of the linker-toxin to the Ab.

61. An antibody-drug conjugate composition comprising the antibody-drug conjugate of claim 60, wherein the composition comprises a multiplicity of drug-antibody ratio (DAR) species, wherein the average DAR of the composition is 2-4.

62. An antibody-drug conjugate comprising an antibody (Ab) and one or more linker-toxins of the following structure:



;

wherein:

Ab is a tissue factor (TF) antibody, wherein the Ab comprises a heavy chain sequence that is QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG and a light chain sequence that is DIQMTQSPSTLSASVGDRVTITCQASQSINNWLAWYQQKPGKAPKLLIYKAYNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, and

the one or more linker-toxins are attached to the Ab through a covalent bond; and

represents a point of attachment of the linker-toxin to the Ab.

63. An antibody-drug conjugate composition comprising the antibody-drug conjugate of claim 62, wherein the composition comprises a multiplicity of drug-antibody ratio (DAR) species, wherein the average DAR of the composition is 2-4.

9. 64. The antibody-drug conjugate of any one of the preceding claims 1-8, wherein:

the Ab is multispecific.; and/or

~~**65.** The antibody-drug conjugate of any one of the preceding claims, wherein the Ab is~~the Ab comprises a Fab, Fab', $F(ab')_2$, Fv, scFv, $(scFv)_2$, single chain antibody molecule, dual variable domain antibody, single variable domain antibody, linear antibody, or V domain antibody~~.~~; and/or

~~**66.** The antibody-drug conjugate of any one of~~ the ~~preceding claims, wherein the antibody~~Ab comprises a scaffold, optionally wherein the scaffold is Fc, optionally human Fc~~.~~

~~**67.** The antibody-drug conjugate of any one of the preceding claims, wherein the antibody comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.~~

~~**68.** The antibody-drug conjugate of claim 67, wherein the antibody comprises a heavy chain constant region of the class IgG, wherein the heavy chain constant region is from a subclass selected from IgG1, IgG2, IgG3, and IgG4.~~

~~**69.** The antibody-drug conjugate of claim 68, wherein the antibody comprises a heavy chain constant region of IgG1.~~

~~**70.** The antibody-drug conjugate of claim 66,~~, optionally wherein the Fc comprises one or more modifications, wherein the one or more modifications result in increased half-life, increased antibody-dependent cellular cytotoxicity (ADCC), increased antibody-dependent cellular phagocytosis (ADCP), increased complement-dependent cytotoxicity (CDC), or decreased effector function, compared with the Fc without the one or more modifications~~.~~; and/or

the Ab comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM, optionally wherein the Ab comprises a heavy chain constant region of the class IgG, wherein the heavy chain constant region is from a subclass selected from IgG1, IgG2, IgG3, and IgG4.

~~**71.**~~ **10.**The antibody-drug conjugate of any one of claims 1~~-70,~~-9, wherein, upon administration to a tumor-bearing subject, the antibody-drug conjugate ~~reduces~~is able to reduce tumor volume or ~~inhibits~~inhibit tumor growth~~.~~ in the subject; and/or

~~**72.** The antibody-drug conjugate of any one of claims 1-71, wherein, upon administration to a tumor-bearing subject,~~ the antibody-drug conjugate ~~reduces~~is able to reduce tumor volume or tumor growth in a tumor-bearing subject by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%,

about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%.%; and/or

73. The antibody-drug conjugate of any one of claims 1-72, wherein, upon administration to a tumor-bearing subject, the antibody-drug conjugate inhibits tumor growth by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%.

74. The antibody-drug conjugate of any one of claims 1-73, wherein, upon administration of the antibody-drug conjugate to a subject, the antibody-drug conjugate does not result in measurable skin toxicity.

75. The antibody-drug conjugate of any one of claims 1-73, wherein, upon administration of the antibody-drug conjugate to a subject, the antibody-drug conjugate or results in reduced skin toxicity relative to a different anti-TF antibody-drug conjugate (ADC.); and/or

76. The antibody-drug conjugate of any one of claims 1-75, wherein administration of the antibody-drug conjugate to a subject does not require administration of one or more anti-inflammatory agents.

77. The antibody-drug conjugate of any one of claims 1-75, wherein administration of the antibody-drug conjugate to a subject, or results in a reduced need for one or more anti-inflammatory agents relative to a different anti-TF ADC.

78. The antibody-drug conjugate of claim 76 or 77,, optionally wherein the one or more anti-inflammatory agents comprises at least one of topical steroids and systemic steroids.; and/or

79. The antibody-drug conjugate of any one of claims 1-78, wherein, upon administration of the antibody-drug conjugate to a subject, the antibody-drug conjugate results in reduced or absent neutropenia in the subject relative to baseline levels.

80. The antibody-drug conjugate of any one of claims 1-78, wherein, upon administration of the antibody-drug conjugate to a subject, the antibody-drug conjugate or does not alter, increase or decrease the number of monocytes in the subject relative to baseline levels.

81. The antibody-drug conjugate of any one of claims 75-80, wherein the different anti-TF ADC is identical to the antibody-drug conjugate except for being conjugated to MMAE.

82. 11. A pharmaceutical composition comprising the antibody-drug conjugate of any one of the preceding claims 1-10 and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 11, wherein the composition comprises a multiplicity of drug-antibody ratio (DAR) species, wherein the average DAR of the composition is 2-4.

13. ~~**83.**~~ Use of the antibody-drug conjugate of any one of claims ~~A~~0-10 or the pharmaceutical composition of claim 11 or 12, in the manufacture of a medicament for ~~method of~~ treating or preventing a disease or condition in a subject in need thereof, ~~comprising administering to the~~ optionally a human subject ~~an effective amount of~~ , optionally wherein

the ~~antibody-drug conjugate of any one of claims 1-81 or the pharmaceutical composition of claim 82.~~

~~**84.** A method of~~treating or preventing is treating or delaying the onset of cancer in a subject in need thereof, ~~comprising administering to the subject an effective amount of the antibody-drug conjugate of any one of claims 1-81.~~

~~**85.** The method of claim 83, wherein the disease or condition is cancer.~~

~~**86.** The method of claim 84 or 85,~~optionally wherein the cancer is selected from the group consisting of: head and neck cancer, ovarian cancer, gastric cancer, esophageal cancer, cervical cancer, prostate cancer, pancreatic cancer, estrogen receptors negative (ER-) breast cancer, progesterone receptors negative (PR ~~)~~ -) breast cancer, HER2 negative (HER2-) triple negative breast cancer, glioblastoma, lung cancer, bladder cancer, melanoma, and kidney cancer~~.~~, or

~~**87.**The method of claim 83,~~ wherein the disease or condition involves neovascularization~~.~~

~~**88.** The method of claim 87,~~, optionally wherein the disease or condition involving neovascularization is cancer~~.~~, or

~~**89.** The method of claim 83,~~ wherein the disease or condition involves vascular inflammation.

~~**90.**~~ The ~~method~~use of ~~any one of claims 83-89,~~claim 13, wherein ~~further~~ ~~comprising administering~~ one or more additional therapeutic agents is to be further administered to the subject~~.~~

~~**91.** The method of claim 90, wherein the composition further comprises the one or more additional therapeutic agents.~~

14. ~~**92.** The method of claim 90,~~, optionally wherein~~:~~

the one or more additional therapeutic ~~agent~~agents is formulated in a different pharmaceutical composition~~.~~; or

~~**93.** The method of claim 90, wherein~~ the one or more additional therapeutic ~~agent~~agents is to be administered prior to administration~~ering~~ of the ~~composition.~~antibody-drug conjugate; or

~~**94.** The method of claim 90, wherein~~ the one or more additional therapeutic ~~agent~~agents is to be administered after administration~~ering~~ of the ~~composition.~~antibody-drug conjugate; or


~~**95.** The method of claim 90, wherein~~ the one or more additional therapeutic ~~agent~~agents is to be administered contemporaneously with the ~~composition~~antibody-drug conjugate.

~~**96.** The method of any one of the preceding claims, wherein the subject is a human subject.~~

~~**97.** A method of killing a cancer cell, comprising contacting the cancer cell with an effective amount of the antibody-drug conjugate of any one of claims 1-81.~~

~~**98.**~~ **15.** A process for preparing an antibody-drug conjugate, the process comprising:

(A) ~~—~~ reacting a nucleophilic or an electrophilic group on an antigen binding protein (Ab) which binds ~~to the extracellular domain of~~ human Tissue Factor (TF) (SEQ ID NO:810) with a bifunctional linker, or with a first linker component of a bifunctional linker that comprises two or more linker components followed by sequential addition of the remaining linker component(s), to form an Ab-linker intermediate, and reacting the Ab-linker intermediate with the -NH_2 group of a compound of general Formula **I**:




Formula I

wherein:

X is *-C(O)NHCH(CH_2(R^2))-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula **I**, or X is absent;

R^1 is selected from the group consisting of:



wherein # and % represent the respective points of attachment as indicated in Formula **I**; and R^2 is phenyl,

to provide the antibody drug conjugate; or

(B) reacting the -NH_2 group on the compound of general Formula **I** with a bifunctional linker ~~to form a linker-toxin intermediate, and reacting the linker-toxin intermediate with a nucleophilic or an electrophilic group on an antigen binding protein (Ab) which binds to the extracellular domain of human Tissue Factor (TF) (SEQ ID NO: 810) to provide the antibody-drug conjugate, wherein, in (A) or (B),~~

~~(a) the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein~~

~~i. the VH-CDR1 comprises SEQ ID NO: 872, the VH-CDR2 comprises SEQ ID NO: 873, the VH-CDR3 comprises SEQ ID NO: 874, the VL-CDR1 comprises SEQ ID NO: 875, the VL-CDR2 comprises SEQ ID NO: 876, and the VL-CDR3 comprises SEQ ID NO: 877,~~

~~ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A3,~~


~~iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A,~~

iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5,

v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25A5-T, or

vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody designated 25G1; and

(b) the antibody-drug conjugate comprises one or more moieties represented by Formula IV:



Formula IV


wherein:

X is *-C(O)NHCH($CH_2(R^2)$)-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula IV, or X is absent;

L is a linker;

! represents the point of attachment of L to the Ab, where L is attahced to the Ab through a covalent bond;

R^1 is selected from the group consisting of:




wherein # and % represent the respective points of attachment as indicated in Formula VI; and

R^2 is phenyl.

99. A process for preparing an antibody-drug conjugate, the process comprising:

(A) reacting a nucleophilic or an electrophilic group on an antigen binding protein (Ab) which binds to the extracellular domain of human Tissue Factor (TF) (SEQ ID NO:810), or with a first linker component of a bifunctional linker that comprises two or more linker components followed by sequential addition of the remaining linker component(s)), to form an Ab-a linker-toxin intermediate, and reacting the Ab-linker-toxin intermediate with the $-NH_2$a nucleophilic or an electrophilic group of a compound of general Formula **I**:on an Ab which binds human TF (SEQ ID NO: 810) to provide the antibody-drug conjugate, wherein, in (A) or (B),

the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein




Formula I

wherein:

X is *-C(O)NHCH(CH_2(R^2))$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula **I**, or X is absent;

R^1 is selected from the group consisting of:



, and

wherein # and % represent the respective points of attachment as indicated in Formula **I**; and R^2 is phenyl,

~~to provide the antibody-drug conjugate; or~~

~~(B) reacting the $-NH_2$ group on the compound of general Formula **I** with a first linker component of a bifunctional linker that comprises two or more linker components followed by sequential addition of the remaining linker component(s) to form a linker-toxin intermediate, and reacting the linker-toxin intermediate with a nucleophilic or an electrophilic group on an antigen binding protein (Ab) which binds to the extracellular domain of human Tissue Factor (TF) (SEQ ID NO: 810) to provide the antibody-drug conjugate, wherein, in (A) or (B),~~

~~(a) the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein~~

~~vii.~~i. the VH-CDR1 comprises the sequence of SEQ ID NO: 872, the VH-CDR2 comprises the sequence of SEQ ID NO: 873, the VH-CDR3 comprises the sequence of SEQ ID NO: 874, the VL-CDR1 comprises SEQ ID NO: 875, the VL-CDR2 comprises the sequence of SEQ ID NO: 876, and the VL-CDR3 comprises the sequence of SEQ ID NO: 877,

~~viii.~~ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody~~Ab designated 25A3,

iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A,

~~ix.~~ the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody designated 25A,~~


~~x.~~iv. ~~the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody~~Ab designated 25A5,

v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A5-T, or

~~xi.~~ the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the ~~antibody designated 25A5-T, or~~

~~xii.~~vi. ~~the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the antibody~~Ab designated 25G1; ~~and~~

~~(b)~~ ~~resulting in~~ the antibody-drug conjugate which comprises one or more moieties represented by Formula IV:



Formula IV


wherein:

X is *-C(O)NHCH($CH_2(R^2)$)-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula IV, or X is absent;

L is a linker;

! represents the point of attachment of L to the Ab, where L is ~~attahced~~attached to the Ab through a covalent bond;

R^1 is selected from the group consisting of:



wherein # and % represent the respective points of attachment as indicated in Formula ~~VI~~IV; and


R^2 is phenyl.

16. ~~**100.**~~ The process according to claim ~~98 or claim 99,~~15, wherein~~:~~

the nucleophilic or electrophilic group on the Ab is a thiol or an amine~~.~~

~~**101.** The process according to claim 100,~~, optionally further comprising ~~treating~~contacting the Ab with a reducing agent to reduce one or more disulfide linkages in the Ab to provide the nucleophilic thiol group~~.~~; and/or

~~**102.** The process according to any one of claims 98-101,~~ wherein L is represented by:



Formula VII

wherein:

Z represents a functional group that binds to a target group of the Ab;

D represents the point of attachment to the amino group as indicated in Formula **I**;

Str is a stretcher;

AA_1 and AA_2 are each independently an amino acid, wherein AA_1-$[AA_2]_m$ forms a protease cleavage site;

X is a self-immolative group;

s is an integer selected from ~~0~~1 and ~~1~~0;

m is an integer selected from the group consisting of 1, 2, 3, and 4; and

o is an integer selected from 0, 1, and 2.

17. ~~**103.**~~ A kit comprising:

(i) the antibody-drug conjugate of any one of claims ~~1-81~~1-10 or the pharmaceutical composition of claim ~~82,~~11 or 12; and (ii) instructions for use.

18. The antibody-drug conjugate of any one of claims 0-10 or the pharmaceutical composition of claim 11 or 12 for use in therapy.